Agios Pharmaceuticals, Inc. (0HB0.L)
USD 28.46
(4.13%)
USD 28.46
(4.13%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 17.31 Million USD | -4409.12% |
| 2022 | -6.02 Million USD | 67.92% |
| 2021 | -18.77 Million USD | -0.03% |
| 2020 | -18.77 Million USD | -118.78% |
| 2019 | 99.97 Million USD | 16.5% |
| 2018 | 85.81 Million USD | 134.37% |
| 2017 | -249.67 Million USD | -66.15% |
| 2016 | -150.27 Million USD | -81.69% |
| 2015 | -82.7 Million USD | -136.22% |
| 2014 | -35.01 Million USD | -20.93% |
| 2013 | -28.95 Million USD | -81.75% |
| 2012 | -15.93 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -70.28 Million USD | -1231.01% |
| 2024 Q3 | 8.18 Million USD | 109.73% |
| 2024 Q1 | 6.21 Million USD | 21.51% |
| 2023 Q1 | 657 Thousand USD | 236.88% |
| 2023 Q4 | 5.11 Million USD | -0.56% |
| 2023 FY | 17.31 Million USD | 387.55% |
| 2023 Q3 | 5.14 Million USD | 350.35% |
| 2023 Q2 | 1.14 Million USD | 73.82% |
| 2022 Q3 | -1.49 Million USD | -500.8% |
| 2022 FY | -6.02 Million USD | 67.92% |
| 2022 Q4 | -480 Thousand USD | 67.89% |
| 2022 Q2 | 373 Thousand USD | 108.44% |
| 2022 Q1 | -4.42 Million USD | -101.22% |
| 2021 Q1 | -4.89 Million USD | -103.03% |
| 2021 Q2 | -4.69 Million USD | 4.15% |
| 2021 Q3 | -4.57 Million USD | 2.45% |
| 2021 Q4 | 362.73 Million USD | 8023.5% |
| 2021 FY | -18.77 Million USD | -0.03% |
| 2020 Q4 | 161.38 Million USD | 410.7% |
| 2020 Q1 | -55.35 Million USD | 22.14% |
| 2020 Q2 | -54.08 Million USD | 2.3% |
| 2020 FY | -18.77 Million USD | -118.78% |
| 2020 Q3 | -51.94 Million USD | 3.96% |
| 2019 FY | 99.97 Million USD | 16.5% |
| 2019 Q4 | -71.09 Million USD | 6.5% |
| 2019 Q2 | -81.47 Million USD | -24.02% |
| 2019 Q3 | -76.04 Million USD | 6.66% |
| 2019 Q1 | -65.69 Million USD | -1.85% |
| 2018 Q2 | -46.31 Million USD | 33.32% |
| 2018 FY | 85.81 Million USD | 134.37% |
| 2018 Q4 | -64.49 Million USD | 5.23% |
| 2018 Q3 | -68.05 Million USD | -46.94% |
| 2018 Q1 | -69.46 Million USD | -3.03% |
| 2017 Q3 | -61.55 Million USD | 10.09% |
| 2017 Q4 | -67.41 Million USD | -9.52% |
| 2017 FY | -249.67 Million USD | -66.15% |
| 2017 Q1 | -52.22 Million USD | -24.25% |
| 2017 Q2 | -68.47 Million USD | -31.11% |
| 2016 Q1 | -12.75 Million USD | 58.47% |
| 2016 Q2 | -43.82 Million USD | -243.54% |
| 2016 Q3 | -51.65 Million USD | -17.87% |
| 2016 FY | -150.27 Million USD | -81.69% |
| 2016 Q4 | -42.03 Million USD | 18.64% |
| 2015 FY | -82.7 Million USD | -136.22% |
| 2015 Q3 | -30.54 Million USD | -31.65% |
| 2015 Q2 | -23.2 Million USD | -1419.16% |
| 2015 Q1 | 1.75 Million USD | 108.7% |
| 2015 Q4 | -30.71 Million USD | -0.55% |
| 2014 Q3 | 8.37 Million USD | 159.12% |
| 2014 FY | -35.01 Million USD | -20.93% |
| 2014 Q4 | -20.22 Million USD | -341.53% |
| 2014 Q1 | -8.99 Million USD | -5.4% |
| 2014 Q2 | -14.16 Million USD | -57.46% |
| 2013 Q4 | -8.53 Million USD | 0.0% |
| 2013 Q1 | -5.19 Million USD | -5.08% |
| 2013 Q2 | -6.69 Million USD | -28.8% |
| 2013 Q3 | -8.53 Million USD | -27.58% |
| 2013 FY | -28.95 Million USD | -81.75% |
| 2012 FY | -15.93 Million USD | 0.0% |
| 2012 Q4 | -4.94 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 5633.227% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -17.068% |
| Editas Medicine, Inc. | -99.52 Million USD | 117.401% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -72.466% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 281.047% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 99.935% |
| uniQure N.V. | 2.21 Million USD | -681.896% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 120.324% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 95.216% |
| bluebird bio, Inc. | -4.03 Million USD | 529.752% |
| Blueprint Medicines Corporation | 236.58 Million USD | 92.68% |
| Adicet Bio, Inc. | -6.09 Million USD | 384.011% |
| Dynavax Technologies Corporation | 182.11 Million USD | 90.49% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 99.669% |
| Myriad Genetics, Inc. | 476.4 Million USD | 96.365% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.063% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 98.415% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 96.693% |
| Verastem, Inc. | -62 Thousand USD | 28033.871% |
| Waters Corporation | 1.76 Billion USD | 99.017% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 99.799% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 99.886% |
| Biogen Inc. | 7.3 Billion USD | 99.763% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 6031.164% |
| Perrigo Company plc | 1.68 Billion USD | 98.969% |
| Imunon, Inc. | -720 Thousand USD | 2505.4% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 76.297% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 99.202% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -5634.768% |
| Geron Corporation | -123.5 Million USD | 114.023% |
| Illumina, Inc. | 2.74 Billion USD | 99.369% |
| Homology Medicines, Inc. | -7.22 Million USD | 339.577% |
| Nektar Therapeutics | 53.47 Million USD | 67.615% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 187.918% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 155.567% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 99.091% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 138.211% |
| Evolus, Inc. | 140.52 Million USD | 87.676% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 99.847% |
| FibroGen, Inc. | 128.9 Million USD | 86.564% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 99.5% |
| OPKO Health, Inc. | 318.12 Million USD | 94.556% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 98.859% |
| Exelixis, Inc. | 1.75 Billion USD | 99.015% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 104.343% |
| Zoetis Inc. | 5.83 Billion USD | 99.703% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 92.918% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 5815.842% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 97.775% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 96.361% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 97.281% |
| Insmed Incorporated | 239.63 Million USD | 92.773% |
| TG Therapeutics, Inc. | 219.1 Million USD | 92.096% |
| Incyte Corporation | 3.44 Billion USD | 99.497% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 94.964% |